Apoptosis: Targets in pancreatic cancer

被引：119
作者：
Sabine Westphal
Holger Kalthoff
机构：
[1] Department of Molecular Oncology, Clinic for General/Thoracic Surgery, University of Kiel, 24105 Kiel
来源：
Molecular Cancer | / 2卷 / 1期
关键词：
Apoptosis; Oncologic therapies; Pancreatic cancer;
D O I：
10.1186/1476-4598-2-6
中图分类号：
学科分类号：
摘要：
Pancreatic adenocarcinoma is characterized by poor prognosis, because of late diagnosis and lack of response to chemo- and/or radiation therapies. Resistance to apoptosis mainly causes this insensitivity to conventional therapies. Apoptosis or programmed cell death is a central regulator of tissue homeostasis. Certain genetic disturbances of apoptotic signaling pathways have been found in carcinomas leading to tumor development and progression. In the past few years, the knowledge about the complex pathways of apoptosis has strongly increased and new therapeutic approaches based on this knowledge are being developed. This review will focus on the role of apoptotic proteins contributing to pancreatic cancer development and progression and will demonstrate possible targets to influence this deadly disease. © 2003 Westphal and Kalthoff; licensee BioMed Central Ltd.
引用
收藏
页数：14
相关论文
共 160 条
[51]  
Friess H., Lu Z., Andren-Sandberg A., Berberat P., Zimmermann A., Adler G., Schmid R., Buchler M.W., Moderate activation of the apoptosis inhibitor Bcl-xL worsens the prognosis in pancreatic cancer, Ann. Surg., 228, pp. 780-787, (1998)
[52]  
Hsu Y.T., Wolter K.G., Youle R.J., Cytosol-to-membrane redistribution of Bax and Bcl-x(L) during apoptosis, Proc. Natl. Acad. Sci. U S A, 94, pp. 3668-3672, (1997)
[53]  
Finucane D.M., Bossy-Wetzel E., Waterhouse N.J., Cotter T.G., Green D.R., Bax-induced caspase activation and apoptosis via cytochrome c release from mitochondria is inhibitable by Bcl-xL, J. Biol. Chem., 274, pp. 2225-2233, (1999)
[54]  
Xu Z.W., Friess H., Buchler M.W., Solioz M., Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents, Cancer Chemother. Pharmacol., 49, pp. 504-510, (2002)
[55]  
Pirocanac E.C., Nassirpour R., Yang M., Wang J., Nardin S.R., Gu J., Fang B., Moossa A.R., Hoffmann R.M., Bouvet M., Bax-induction gene therapy of pancreatic cancer, J. Surg. Res., 106, pp. 346-351, (2002)
[56]  
Seki T., Ohba N., Makino R., Funatomi H., Mitamura K., Mechanism of growth-inhibitory effect of cisplatin on human pancreatic cancer cells and status of p53 gene, Anticancer Res., 21, pp. 1919-1924, (2001)
[57]  
Graber H.U., Friess H., Zimmermann A., Korc M., Adler G., Schmid R., Bchler M.W., Bak expression and cell death occur in peritumorous tissue but not in pancreatic cancer cells, J. Gastrointest Surg., 3, pp. 74-80, (1999)
[58]  
Adachi M., Imai K., The proapoptotic BH3-only protein BAD transduces cell death signals independently of its interaction with Bcl-2, Cell Death and Differ., 9, pp. 1240-1247, (2002)
[59]  
Baell J.B., Huang D.C., Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs, Biochem. Pharmacol., 64, pp. 851-863, (2002)
[60]  
Ding X.Z., Tong W.G., Adrian T.E., Cyclooxygenases and lipoxygenases as potential targets for treatment of pancreatic cancer, Pancreatology, 1, pp. 291-299, (2001)
12345678910